Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Blood disorders, 2010. Verfasst von Osama Moussa und 2 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment. Some of these newer drugs are in the advanced stages of clinical trials or have already completed them and thereby aim to provide more options in the management of thromboembolism. In the present review we discuss the currently available evidence supporting the use of these new anticoagulants, in particular rivaroxaban.
Zitieren
APA
Moussa, O., Chattopadhyay, D., & Bhattacharya, V. (2010). Update on Rivaroxaban. Clinical medicine. Blood disorders. https://doi.org/10.4137/cmbd.s5101
Vancouver
Moussa O, Chattopadhyay D, Bhattacharya V. Update on Rivaroxaban. Clinical medicine. Blood disorders. 2010. doi:10.4137/cmbd.s5101
BibTeX
@article{Moussa2010,
author = {Moussa, Osama and Chattopadhyay, Dipankar and Bhattacharya, Vish},
title = {Update on Rivaroxaban},
journal = {Clinical medicine. Blood disorders},
year = {2010},
doi = {10.4137/cmbd.s5101}
}
EUVIMED